International Stem Cell CORP 8-K filings
Current reports — the filing a company makes when something happens that shareholders need to know about before the next quarterly report.
OQB
International Stem Cell Corporation stockholders elected four directors at the 2026 Annual Meeting held on June 11, 2026.
OQB
International Stem Cell Corporation held its Annual Meeting, electing four directors and approving executive compensation on an advisory basis.
OQB
International Stem Cell Corporation has extended the maturity date of a $2.5 million loan from its Co-Chairman and CEO, Dr. Andrey Semechkin, until September 15, 2026, highlighting ongoing financial reliance.
OQB
International Stem Cell Corporation has extended the maturity date of a $2.9 million loan by issuing a new $2.7 million promissory note to Dr. Andrey Semechkin, with a maturity date of September 15, 2025.